Literature DB >> 15127421

Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions.

Elisabeth Fenwick1, Bernie J O'Brien, Andrew Briggs.   

Abstract

Cost-effectiveness acceptability curves (CEACs) have been widely adopted as a method to quantify and graphically represent uncertainty in economic evaluation studies of health-care technologies. However, there remain some common fallacies regarding the nature and shape of CEACs that largely result from the 'textbook' illustration of the CEAC. This 'textbook' CEAC shows a smooth curve starting at probability 0, with an asymptote to 1 for higher money values of the health outcome (lambda). But this familiar 'ogive' shape which makes the 'textbook' CEAC look like a cumulative distribution function is just one special case of the CEAC. The reality is that the CEAC can take many shapes and turns because it is a graphic transformation from the cost-effectiveness plane, where the joint density of incremental costs and effects may 'straddle' quadrants with attendant discontinuities and asymptotes. In fact CEACs: (i) do not have to cut the y-axis at 0; (ii) do not have to asymptote to 1; (iii) are not always monotonically increasing in lambda; and (iv) do not represent cumulative distribution functions (cdfs). Within this paper we present a 'gallery' of CEACs in order to identify the fallacies and illustrate the facts surrounding the CEAC. The aim of the paper is to serve as a reference tool to accompany the increased use of CEACs within major medical journals. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 15127421     DOI: 10.1002/hec.903

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  306 in total

1.  The incremental cost-effectiveness of engaging private practitioners to refer tuberculosis suspects to DOTS services in Jogjakarta, Indonesia.

Authors:  Yodi Mahendradhata; Ari Probandari; Riris A Ahmad; Adi Utarini; Laksono Trisnantoro; Lars Lindholm; Marieke J van der Werf; Michael Kimerling; Marleen Boelaert; Benjamin Johns; Patrick Van der Stuyft
Journal:  Am J Trop Med Hyg       Date:  2010-06       Impact factor: 2.345

Review 2.  Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.

Authors:  Christine M Nguyen; Mark Bounthavong; Margaret A S Mendes; Melissa L D Christopher; Josephine N Tran; Rashid Kazerooni; Anthony P Morreale
Journal:  Pharmacoeconomics       Date:  2012-07-01       Impact factor: 4.981

3.  Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.

Authors:  Salah Ghabri; Françoise F Hamers; Jean Michel Josselin
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

4.  Cost effectiveness of a program to promote screening for cervical cancer in the Vietnamese-American population.

Authors:  John F Scoggins; Scott D Ramsey; J Carey Jackson; Victoria M Taylor
Journal:  Asian Pac J Cancer Prev       Date:  2010

5.  Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.

Authors:  Katia Noyes; Andrew W Dick; Robert G Holloway
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 6.  Economic evaluations: a new avenue of outcome assessment in spinal disorders.

Authors:  Nicole van der Roer; Norbert Boos; Maurits W van Tulder
Journal:  Eur Spine J       Date:  2005-12-01       Impact factor: 3.134

Review 7.  Health economic evaluation in lumbar spinal fusion: a systematic literature review anno 2005.

Authors:  Rikke Soegaard; Finn B Christensen
Journal:  Eur Spine J       Date:  2005-12-21       Impact factor: 3.134

Review 8.  Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions?

Authors:  Mark J Sculpher; Michael F Drummond
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

9.  Transforaminal lumbar interbody fusion vs. posterolateral instrumented fusion: cost-utility evaluation along side an RCT with a 2-year follow-up.

Authors:  A Christensen; K Høy; C Bünger; P Helmig; E S Hansen; T Andersen; R Søgaard
Journal:  Eur Spine J       Date:  2014-02-21       Impact factor: 3.134

10.  Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.

Authors:  Gerardo Machnicki; Jean-Francois Ricci; Daniel C Brennan; Mark A Schnitzler
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.